Huntington's disease: pathogenesis to animal models.
Journal Title: Pharmacological Reports - Year 2010, Vol 62, Issue 1
Abstract
Huntington's disease (HD) is an inherited genetic disorder, characterized by cognitive dysfunction and abnormal body movements called chorea. George Huntington, an Ohio physician, described the disease precisely in 1872. HD is a dominantly inherited disorder, characterized by progressive neurodegeneration of the striatum but also involves other regions, primarily the cerebral cortex. The mutation responsible for this fatal disease is an abnormally expanded and unstable CAG repeat within the coding region of the gene encoding the huntingtin protein. Various hypotheses have been put forward to explain the pathogenic mechanisms of mutant huntingtin-induced neuronal dysfunction and cell death. None of these hypotheses, however, offers a clear explanation; thus, it remains a topic of research interest. HD is considered to be an important disease, embodying many of the major themes in modern neuroscience, including molecular genetics, selective neuronal vulnerability, excitotoxicity, mitochondrial dysfunction, apoptosis and transcriptional dysregulation. A number of recent reports have concluded that oxidative stress plays a key role in HD pathogenesis. Although there is no specific treatment available to block disease progression, treatments are available to help in controlling the chorea symptoms. As animal models are the best tools to evaluate any therapeutic agent, there are also different animal models available, mimicking a few or a larger number of symptoms. Each model has its own advantages and limitations. The present review deals with the pathophysiology and various cascades contributing to HD pathogenesis and progression as well as drug targets, such as dopaminergic, gamma-amino butyric acid (GABA)ergic, glutamate adenosine receptor, peptidergic pathways, cannabinoid receptor, and adjuvant therapeutic drug targets such as oxidative stress and mitochondrial dysfunction that can be targeted for future experimental study. The present review also focuses on the animal models (behavioral and genetic) used to unravel pathogenetic mechanisms and the identification of novel drug targets.
Authors and Affiliations
Puneet Kumar, Harikesh Kalonia, Anil Kumar
Keywords
Related Articles
- EP ID EP96979
- DOI -
- Views 82
- Downloads 0
Preoperative tramadol combined with postoperative small-dose tramadol infusion after total abdominal hysterectomy: a double-blind, randomized, controlled trial.
This double blind, randomized, controlled trial investigated whether a single preoperative intravenous (iv) dose of tramadol (100 mg) given 30 min before abdominal hysterectomy resulted in improved analgesic efficacy, re...
Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice.
Alzheimer's disease (AD) results in an impairment of memory and behavior. It is accepted that amyloid beta (Abeta) peptides are responsible for the etiopathology of AD, but the precise signaling pathways leading to the d...
Glial degeneration as a model of depression.
Major depression (MD) is a common and disabling disorder but knowledge of its pathophysiology is still incomplete. In the last years, degenerations or dysfunctions of glial cells, especially astrocytes, have been postula...
Nitric oxide modulation mediates the protective effect of trazodone in a mouse model of chronic fatigue syndrome.
The present study was conducted with the aim of elucidating the possible role of nitric oxide (NO) in the neuroprotective effects of trazodone used to treat chronic fatigue syndrome (CFS) in mice. Male albino mice were f...
Glyburide for the treatment of gestational diabetes mellitus.
Insulin is the traditional treatment for gestational diabetes mellitus (GDM) unresponsive to dietary interventions. Until recently, oral hypoglycemic drugs had been contraindicated due to concerns regarding teratogenicit...